Company / CapEx per Share
CRISPR Therapeutics AG CapEx per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest CapEx per Share
$0.01
FY2025
5-year range
$0.01 / $1.11
FY2021-FY2025
Trend
-55.1%
vs FY2024
Sector context
#121 of 190
Health Care
What the data says
At $0.01, CRISPR Therapeutics AG's capex per share ranks #121 of 190 in the Health Care sector. CapEx per Share has declined for 4 consecutive years, from $1.11 in FY2021 to $0.01 in FY2025.
Based on SEC 10-K filings.
0.01 in FY2025 with a 5-year CAGR of -48.8%.
Declined from $0.12 to $0.01 over the past 2 years.
Health Care sector context is included.
CapEx per Share over time
Growth rates
- 3-Year CAGR
- -72.0%
- 5-Year CAGR
- -48.8%
- 10-Year CAGR
- -
Sector benchmark
#121 of 190 in Health CareTop 64% of 190This company $0.01 Sector average $2.49
▼
-99.6% below sector average
Key checks
Key Insights
- CRISPR Therapeutics AG's capex per share has declined for 4 consecutive years.
- In FY2025, capex per share decreased 55.1% year-over-year.
- Ranks #121 out of 190 companies in the Health Care sector.
- Peak capex per share was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | CapEx per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.01 | -55.1% |
| FY2024 | $0.02 | -80.3% |
| FY2023 | $0.12 | -75.0% |
| FY2022 | $0.48 | -56.3% |
| FY2021 | $1.11 | +266.0% |
| FY2020 | $0.30 | +134.3% |
| FY2019 | $0.13 | +88.7% |
| FY2018 | $0.07 | -65.3% |
| FY2017 | $0.20 | -63.9% |
| FY2016 | $0.55 | +138.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026